Grifols Alzheimer’s vaccine appears safe, but efficacy unclear, in PhII study

24 Oct 2023

Phase 2Clinical ResultVaccine

An experimental Alzheimer’s vaccine that stimulates the immune system to remove forms of amyloid proteins that accumulate in blood vessels appeared safe in a study of patients with mild cognitive impairment or mild Alzheimer’s disease. People in the Phase II, 134 patient study were assessed a year after they received the first of 6 shots. When measured on a common test for cognitive impairment called the Mini-Mental State Examination (MMSE), their disease slowed by a maximum of 38% in people who got the vaccines compared to placebo. That result was statistically significant. But a later review at 18 months and 24 months, which showed an 18% slowing of disease, was not.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Indications

Cognitive DysfunctionAlzheimer Disease

Targets

Drugs

Human plasma-derived fibrinolysin (Grifols)Human Alzheimer's DNA Vaccine(Institute for Molecular Medicine Finland)

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.